Regardless of the patient’s HPV status, 40%–60% of penile cancers show a high level of PD-L1 expression which, although associated with decreased cancer-specific survival, could nevertheless be a rationale for a checkpoint inhibitor-based treatment approach (3, 24). This evidence concerns the gene CD274 and penile cancer.